|1.||Yang, Dajun: 4 articles (01/2011 - 01/2008)|
|2.||Sun, Jian: 3 articles (11/2015 - 07/2009)|
|3.||Hu, Zhe-Yu: 3 articles (07/2015 - 07/2009)|
|4.||Wu, Daocheng: 3 articles (01/2015 - 04/2009)|
|5.||Xu, Liang: 3 articles (01/2015 - 04/2009)|
|6.||Aboukameel, Amro: 3 articles (04/2010 - 01/2008)|
|7.||Mohammad, Ramzi M: 3 articles (04/2010 - 01/2008)|
|8.||Chen, Jianyong: 3 articles (04/2010 - 01/2008)|
|9.||Zhan, Yonghua: 2 articles (08/2013 - 04/2009)|
|10.||Banerjee, Sanjeev: 2 articles (04/2010 - 09/2008)|
01/01/2008 - "Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model."
07/01/2015 - "Apogossypolone induces reactive oxygen species accumulation and controls cell cycle progression in Raji Burkkit's lymphoma cells."
07/01/2009 - "We examined the effect of apogossypolone (ApoG2), a new derivative from gossypol on cell cycle regulation in U937 human leukemic monocyte lymphoma cells in vitro. "
01/01/2008 - "This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
04/01/2010 - "Apogossypolone, which functions as a potent pan-Bcl-2 family inhibitor, seems therapeutically promising for future translational studies including the treatment of pancreatic cancer."
04/01/2010 - "Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells."
08/30/2012 - "This may account for the preferential cytotoxicity of apogossypolone towards tumor cells."
04/01/2009 - "The results indicate that apogossypolone exerts strong antitumor activities in human prostate and breast cancer cells, and thus represents a promising cancer therapeutic."
01/01/2013 - "Apogossypolone (ApoG2), a novel derivative of gossypol, exhibits superior antitumor activity in Bcl-2 transgenic mice, and induces autophagy in several cancer cells. "
08/19/2013 - "Apogossypolone (ApoG2), a potent small molecular inhibitor of Bcl-2 family proteins, is reported to have a significant anti-cancer effect in several types of cancers, but it has not been investigated in gastric cancer. "
11/01/2015 - "As a novel gossypol derivative targeting antiapoptotic proteins of the Bcl‑2 family, apogossypolone (ApoG2) exhibits antitumor properties in various cancer types, although its effects against CRC remain to be fully elucidated. "
|5.||Hepatocellular Carcinoma (Hepatoma)
01/01/2013 - "The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma [corrected] cells."
12/01/2008 - "To investigate the in vitro and in vivo activities and related mechanism of apogossypolone (ApoG2) alone or in combination with adriamycin (ADM) against human hepatocellular carcinoma (HCC). "
12/01/2008 - "Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma."
|1.||Proteins (Proteins, Gene)
|4.||Reactive Oxygen Species (Oxygen Radicals)
|9.||Hyaluronic Acid (Hyaluronan)